Gemcitabine – a major advance?

Thomas, Anne; Steward, W.P.

doi:10.1023/a:1008498219576

Cited by 13 publications

(10 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients treated with different gemcitabine doses, from 800 to 1800 mg per square meter of body surface area, were analyzed, and a wider concentration range than found was chosen to asses the linearity of our method. Data obtained from triplicate determinations of five concentrations in the range found in patients: dFdCDP (0.18, 0.5, 1, 2, and 3 g mL −1 ), dFdCTP (0.2, 0.9, 1.8, 2.5, and 3 g mL −1 ), ADP (0.3, 2.5, 7, 11, and 15 g mL −1 and ATP (2,10,20,30, and 42 g mL −1 ) were fitted by linear least-square analysis with respective r values of 0.9993, 0.998, 0.999, and 0.998. For the linearity test we used the regression variance analysis, which yielded an F value lower than the tabulated at the 0.05 significance level.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Simultaneous determination of gemcitabine di- and triphosphate in human blood mononuclear and cancer cells by RP-HPLC and UV detection

Losa

Sierra

Gion

et al. 2006

Journal of Chromatography B

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

“…Gemcitabine (2 ,2 -difluoro-2 -deoxycytidine; dFdC) is a prodrug with significant activity against solid tumours [1,2]. Structurally, it is a deoxycytidine analog with a modification at the 2 position of the sugar ring.…”

Section: Introductionmentioning

confidence: 99%

Simultaneous determination of gemcitabine di- and triphosphate in human blood mononuclear and cancer cells by RP-HPLC and UV detection

Losa

Sierra

Gion

et al. 2006

Journal of Chromatography B

View full text Add to dashboard Cite

“…This and other experimental findings [20] along with the encouraging therapeutic index of this agent in a number of other solid tumors [5] have stimulated the present investigation of a dose-intensified biweekly regimen in patients with advanced HCC.…”

Section: Discussionmentioning

confidence: 89%

“…Recently, promising results for the treatment of several different solid tumors, including advanced gastrointestinal adenocarcinomas, have been reported with the novel cytidine analog gemcitabine [5]. Despite its documented broad spectrum of activity, favorable toxicity profile, ease of administration in the outpatient setting, as well as its apparent in vitro effectiveness on the human hepatoma cell line HepG2 [6], only preliminary data have been reported in patients with HCC [7].…”

Section: Introductionmentioning

confidence: 99%

Treatment of Advanced Hepatocellular Carcinoma with Biweekly High-Dose Gemcitabine

Ulrich‐Pur

Kornek²,

Fiebiger³

et al. 2001

Oncology

View full text Add to dashboard Cite

Introduction: Until today, an optimal palliative treatment regimen has not been defined for patients with advanced hepatocellular carcinoma. Since the novel cytidine analog gemcitabine has shown strong antitumor effects in vitro in a human hepatoma cell line and its therapeutic potential seems well established in several different tumors including gastrointestinal adenocarcinomas, the present phase II trial using a dose-intensified biweekly administration schedule was initiated. Patients and Methods: 17 patients with histologically confirmed unresectable advanced or metastatic hepatoma were treated with gemcitabine 2,200 mg/m² given as a 30-min intravenous infusion on days 1 and 15. Treatment courses were repeated every 4 weeks. Results: All patients were evaluable for response and toxicity assessment. No objective response was achieved, stable disease occurred in 8 patients (47%), and 9 progressed while on chemotherapy. The median time to progression was 4 months (range 1.5–14 months), and the median survival time was 8.5 months (range 2.5–16.0+ months). Treatment was well tolerated with mild or moderate leukopenia, thrombocytopenia and anemia representing the most common side effects. Gastrointestinal and other subjective toxicities were infrequent and also generally mild. Conclusions: In view of the disappointing treatment results, gemcitabine using this particular dose regimen should not be considered for further investigation in patients with advanced hepatocellular carcinoma.

show abstract

“…Das aufgrund der vornehmlich nur hämatologischen Toxizität (Neutropenie III/IV 0-23,3%, Thrombopenie 0-20,0%) [1] meist benutzte und verträglichste Schema ist die 30-minüti-ge Infusion mit 800-1 200 mg/m 2 [74]. Weitere Untersuchungen legen die MTD bei 1 000-3 500 mg/m 2 fest [31,32].…”

Section: üBersicht üBer Die Klinischen Datenunclassified

Kombination von Radiotherapie und Gemcitabine

Mose

Class

Weber

et al. 2002

Strahlentherapie und Onkologie

View full text Add to dashboard Cite

It is without doubt that data provided by clinical studies are of highest relevance for the evaluation of an optimized radiochemotherapy with Gemcitabine. However, although it is often difficult to transfer experimental data into the clinical situation, these data offer the possibility to develop an improved schedule of administration in patient treatment based on rational evidence in tumor biology.

show abstract

Gemcitabine – a major advance?

Cited by 13 publications

References 11 publications

Simultaneous determination of gemcitabine di- and triphosphate in human blood mononuclear and cancer cells by RP-HPLC and UV detection

Simultaneous determination of gemcitabine di- and triphosphate in human blood mononuclear and cancer cells by RP-HPLC and UV detection

Treatment of Advanced Hepatocellular Carcinoma with Biweekly High-Dose Gemcitabine

Kombination von Radiotherapie und Gemcitabine

Contact Info

Product

Resources

About